Farmacocinética y efectos adversos de la doxiciclina en el tratamiento de la Ehrlichiosis: fundamentos teóricos para ensayos clínicos en caninos

Contenido principal del artículo

Autores

Santiago Monsalve B http://orcid.org/0000-0002-9505-3054 Vanessa Gallego L http://orcid.org/0000-0001-6789-2777 Victor Manuel Molina http://orcid.org/0000-0002-6839-6481 Juan Rodas G http://orcid.org/0000-0002-7054-9918

Resumen

Ehrlichia canis es la bacteria causante de la Ehrlichiosis monocítica canina (EMC), una enfermedad de importancia global en la medicina veterinaria y humana. Varios estudios han abordado la eficacia terapéutica de hidrocloruro de tetraciclina e hiclato de doxiciclina (HD) para el tratamiento de la EMC, sin embargo los resultados obtenidos siguen siendo controvertidos. La doxiciclina es el tratamiento de elección para la EMC, enfermedad bien caracterizada que puede servir como modelo para las investigaciones en el estudio de las enfermedades del orden de los Rickettsiales y las zoonosis transmitidas por garrapatas. Aunque desde décadas atrás se conoce su farmacocinética y la eficacia en el tratamiento de la EMC en fase aguda y subclínica, algunos resultados también indican que Ehrlichia canis puede persistir en perros clínicamente normales, incluso después de un amplio régimen de tratamiento. El propósito de esta revisión es hacer un acercamiento referente a la farmacocinética y los efectos adversos de la doxiciclina en el tratamiento de la EMC.

Palabras clave:

Detalles del artículo

Referencias

1. Aronson AL. Pharmacotherapeutics of the newer tetracyclines. J Am Vet Med Assoc 1980; 176(10):1061–8.

2. Cunha, B.A. Sibley, C.M. Ristuccia AM. Doxyxycline. Ther Drug Monit 1982; 4(2):115. https://doi.org/10.1097/00007691-198206000-00001

3. Riond JL, Vaden SL, Riviere JE. Comparative Pharmacokinetics of Doxycycline in Cats and Dogs. J Vet Pharmacol Ther 1990; 13(4):415–24. https://doi.org/10.1111/j.1365-2885.1990.tb00797.x

4. Barza M, Brown RB, Shanks C, Gamble C, Weinstein L. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob Agents Chemother 1975; 8(6):713–20. https://doi.org/10.1128/AAC.8.6.713

5. Villaescusa A, García-Sancho M, Rodríguez-Franco F, Tesouro MÁ, Sainz Á. Effects of doxycycline on haematology, blood chemistry and peripheral blood lymphocyte subsets of healthy dogs and dogs naturally infected with Ehrlichia canis. Vet J 2015; 204(3):263–8. https://doi.org/10.1016/j.tvjl.2015.03.031

6. Von Wittenau, M.S. Yeary R. The excretion and distribution in body fluids of tetracyclines after intravenous administration to dogs. J Pharmacol Exp Ther 1963; 140(2):258–66.

7. Neer TM, Breitschwerdt EB, Greene RT, Lappin MR. Consensus statement on ehrlichial disease of small animals from the infectious disease study group of the ACVIM. American College of Veterinary Internal Medicine. J Vet Intern Med 2002; 16(3):309–15. https://doi.org/10.1111/j.1939-1676.2002.tb02374.x

8. Sumano H, Ocampo L. Tetraciclinas. Farmacología veterinaria. México: MC Graw Hill; 2006.

9. Chambers HE. Inhibidores de la síntesis de proteína y otros antibacterianos. En: Laurence L. Brunton(Ed). Las Bases Farmacológicas de la Terapéutica. Undécima e. México: MC Graw Hill; 2008.

10. Vicente D, Pérez-Trallero E. Tetraciclinas, sulfamidas y metronidazol. Enferm Infecc Microbiol Clin 2010; 28(2):122–30. https://doi.org/10.1016/j.eimc.2009.10.002

11. Gutiérrez L, Velasco Z, Vázquez C, Vargas D, Sumano H. Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs. Acta Vet Scand 2012; 54(1):1. https://doi.org/10.1186/1751-0147-54-35

12. Deck DH, Winston LG. Tetracyclines, Macrolides, Clindamycin, Chloramphenicol, Streptogramins, & Oxazolidinones. In: Katzung BG, Masters SB, Trevor AJ (editor). Basic & clinical pharmacology. Vol 12. 2012.

13. Schulz BS, Hupfauer S, Ammer H, Sauter-Louis C, Hartmann K. Suspected side effects of doxycycline use in dogs - a retrospective study of 386 cases. Vet Rec 2011; 169(9):229. https://doi.org/10.1136/vr.d4344

14. Bartlett JG, Bustetter LA, Gorbach SL, Andrew B. Comparative Effect of Tetracycline and Doxycycline on the Occurrence of Resistant Escherichia coli in the Fecal Comparative Effect of Tetracycline and Doxycycline on the Occurrence of Resistant Escherichia coli in the Fecal Flora 1975; 7(1):55–7.

15. Little SE. Ehrlichiosis. In: Arthropod Borne Diseases. Springer International Publishing; 2017. https://doi.org/10.1007/978-3-319-13884-8_14

16. Perez M, Bodor M, Zhang C, Xiong Q, Rikihisa Y. Human infection with Ehrlichia canis accompanied by clinical signs in Venezuela. Ann N Y Acad Sci 2006;1078:110–7. https://doi.org/10.1196/annals.1374.016

17. Bouza-mora L, Dolz G, Solórzano-morales A, Romero-zu JJ, Salazar-sánchez L, Labruna MB, et al. Novel genotype of Ehrlichia canis detected in samples of human blood bank donors in Costa Rica. Ticks Tick Borne Dis 2017; 8(1):36–40. https://doi.org/10.1016/j.ttbdis.2016.09.012

18. López, J. Rivera, M. Concha, J. C. Gatica, S. Loeffeholz, M. Barriga O. Ehrlichiosis humana en Chile: evidencia serológica. Rev Med Chil 2003; 131(1):67–70. https://doi.org/10.4067/S0034-98872003000100010

19. Vargas-Hernandez, G., André, M. R., Cendales, D. M., Sousa, K. C. M. D., Gonçalves, L. R., Rondelli., Zacarías-Machado, R., Tinucci-Costa M. Molecular detection of Anaplasma species in dogs in Colombia. Braz J Vet Parasitol 2016; 25(4):459–64. https://doi.org/10.1590/s1984-29612016066

20. Nair ADS, Cheng C, Ganta CK, Sanderson MW, Alleman R, Munderloh UG, et al. Comparative Experimental Infection Study in Dogs with Ehrlichia canis, E . chaffeensis, Anaplasma platys and A . phagocytophilum. PLoS One 2016;11(2):1–21. https://doi.org/10.1371/journal.pone.0148239

21. Miranda J, Mattar S. Molecular detection of Anaplasma sp. and ehrlichia sp. in ticks collected in domestical animals, Colombia. Trop Biomed 2015;32(4):726–35.

22. Waner T, Harrus S, Jongejan F, Bark H, Keysary A. Cornelissen AWCA. Significance of serological testing for ehrlichial diseases in dogs with special emphasis on the diagnosis of canine monocytic ehrlichiosis caused by Ehrlichia canis. Vet Parasitol 2001; 95(1):1–15. https://doi.org/10.1016/S0304-4017(00)00407-6

23. Casas EA. Seroprevalencia de la dirofilariosis y ehrlichiosis canina en tres distritos de Lima. Rev Inv Vet Peru 2003;14(1):43–8.

24. Swann JW, Woods K, Wu Y, Glanemann B, Garden OA. Characterisation of the Immunophenotype of Dogs with Primary Immune-Mediated Haemolytic Anaemia. PLoS One 2016; 11(2):1-18. https://doi.org/10.1371/journal.pone.0168296

25. Mccullough S. Immune-mediated hemolytic anemia : understanding the nemesis. Vet Clin North Am Small Anim Pr 2003; 33:1295–315. https://doi.org/10.1016/j.cvsm.2003.08.003

26. Ge, Y., Yin, H., Rikihisa, Y., Pan, W., & Yin H. Molecular Detection of Tick-Borne Rickettsiales in Goats and Sheep from Southeastern China. Vector-Borne Zoonotic Dis. 2016; 16(5):309–16. https://doi.org/10.1089/vbz.2015.1884

27. Karnezi D, Ceron JJ, Theodorou K, Leontides L, Siarkou VI, Martinez S, et al. Acute phase protein and antioxidant responses in dogs with experimental acute monocytic ehrlichiosis treated with rifampicin. Vet Microbiol 2016; 184:59–63. https://doi.org/10.1016/j.vetmic.2016.01.007

28. Little SE. Ehrlichiosis and Anaplasmosis in Dogs and Cats. Vet Clin North Am - Small Anim Pract 2010; 40(6):1121–40. https://doi.org/10.1016/j.cvsm.2010.07.004

29. Rikihisa Y. Anaplasma phagocytophilum and Ehrlichia chaffeensis : subversive manipulators of host cells. Nat Publ Gr 2010; 8(5):328–39.
https://doi.org/10.1038/nrmicro2318

30. Kucuk A, Kabadere S, Tosun M, Koken T, Kinaci MK, Isikli B, et al. Protective effects of doxycycline in ischemia/reperfusion injury on kidney. J Physiol Biochem 2009; 65(2):183–91. https://doi.org/10.1007/BF03179069

31. Gabler, W.L. Creamer HR. Suppression of human neutrophil functions by tetracyclines. J Periodontal Res 1991; 26(1):52–8. https://doi.org/10.1111/j.1600-0765.1991.tb01626.x

32. Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines : a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010; 299(3):C539-48. https://doi.org/10.1152/ajpcell.00047.2010

33. Frank JR, Breitschwerdt EB. A Retrospective Study of Ehrlichiosis in 62 Dogs from North Carolina and Virginia. J Vet Intern Med 1999; 13(3):194-201. https://doi.org/10.1111/j.1939-1676.1999.tb02178.x

34. De Castro MB, Machado RZ, De Aquino LPCT, Alessi AC, Costa MT. Experimental acute canine monocytic ehrlichiosis: Clinicopathological and immunopathological findings. Vet Parasitol 2004; 119(1):73–86. https://doi.org/10.1016/j.vetpar.2003.10.012

35. Ismail N, Crossley EC, Stevenson HL, Walker DH. Relative Importance of T-Cell Subsets in Monocytotropic Ehrlichiosis : a Novel Effector Mechanism Involved in Ehrlichia -Induced Immunopathology in Murine Ehrlichiosis. Infect Immun 2007; 75(9):4608-4620. https://doi.org/10.1128/IAI.00198-07

36. Winslow GM, Yager E, Shilo K, Volk E, Reilly A, Chu FK. Antibody-Mediated Elimination of the Obligate Intracellular Bacterial Pathogen Ehrlichia chaffeensis during Active Infection. Infect Immun 2000; 68(4):2187-2195. https://doi.org/10.1128/IAI.68.4.2187-2195.2000

37. Harrus S, Waner T, Friedmann-morvinski D. Down-regulation of MHC class II receptors of DH82 cells, following infection with Ehrlichia canis. Vet Immunol Immunopathol 2003; 96(3-4):239-43. https://doi.org/10.1016/j.vetimm.2003.08.005

38. Wilson RC, Kemp DT, Kitzman J V., Goetsch DD. Pharmacokinetics of doxycycline in dogs. Can J Vet Res 1988; 52(1):12–4.

39. Maurin M, Bakken JS, Dumler JS. Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States. Antimicrob Agents Chemother 2003; 47(1):413–5. https://doi.org/10.1128/AAC.47.1.413-415.2003

40. Collins, S.P. Labelle, A.L. Dirikolu, L. Li, Z. Mitchell, M.A. Hamor RE. Tear film concentrations of doxycycline following oral administration in ophthalmologically normal dogs. J Am Vet Med Assoc 2016; 249(5):508–14. https://doi.org/10.2460/javma.249.5.508

41. Arciniegas-Ruiz SM, Gutiérrez-Olvera L, Bernad-Bernad MJ, Caballero-Chacón SDC, Vargas-Estrada D. Comparative pharmacokinetics of a new oral long-acting formulation of doxycycline hyclate: A canine clinical trial. Eur J Pharm Sci 2015; 80:9–15. https://doi.org/10.1016/j.ejps.2015.09.012

42. Vicente D, Pérez-Trallero E. Tetraciclinas, sulfamidas y metronidazol. Enferm Infecc Microbiol Clin 2010; 28(2):122–30. https://doi.org/10.1016/j.eimc.2009.10.002

43. Armijo JA. Absorción, distribución y eliminación de los fármacos. In: editor. Farmacología humana. Barcelona: Masson S.A: 1997.

44. Perez-Trallero E, Iglesias L. Tetraciclinas, sulfamidas y metronidazol. Enferm Infecc Microbiol Clin 2010; 28(2):122–30. https://doi.org/10.1016/j.eimc.2009.10.002

45. Riond J, Riviere JE. Doxycycline binding to plasma albumin of several species. J Vet Pharmacol Ther 1989; 12(3):253-260. https://doi.org/10.1111/j.1365-2885.1989.tb00668.x

46. Bidgood TL, Papich MG. Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. Am J Vet Res 2003; 64(8):1040–6. https://doi.org/10.2460/ajvr.2003.64.1040

47. Passalidou, P. Giudicelli, H. Moreigne, M. Khalfi A. Un cas d'ulcère œsophagien secondaire à la prise de doxycycline. Arch Pédiatrie 2006; 13(1):90–1. https://doi.org/10.1016/j.arcped.2005.10.014

48. Michel, G. Mosser, J. Fauran AU. Serum kinetics of doxycycline polyphosphate in dogs. Eur J Drug Metab Pharmacokinet 1979; 1:43–48. https://doi.org/10.1007/BF03189398

49. Iqbal ZRY. Reisolation of Ehrlichia canis from Blood and Tissues of Dogs after Doxycycline Treatment. J Clin Microbiol 1994; 32(7):1644–9.

50. Breitschwerdt EB, Hegarty BC, Hancock SI, Carolina N, Carolina N. Doxycycline Hyclate Treatment of Experimental Canine Ehrlichiosis Followed by Challenge Inoculation with Two Ehrlichia canis Strains. Antimicrob Agents Chemother 1998; 42(2): 362–368.

51. McClure JC, Crothers ML, Schaefer JJ, Stanley PD, Needham GR, Ewing SA, et al. Efficacy of a doxycycline treatment regimen initiated during three different phases of experimental ehrlichiosis. Antimicrob Agents Chemother 2010; 54(12):5012–20. https://doi.org/10.1128/AAC.01622-09

52. Chiers K, Weyens P, Deprez P, Heerden M van, Meulemans G, Baert K, et al. Lingual and pharyngeal paralysis due to acute doxycycline intoxication in veal calves. Vet Rec 2004;155(1):25–6. https://doi.org/10.1136/vr.155.1.25

53. Riond J, Riviere JE, Duckettt WM, Atkins CE. Cardiovascular effects and fatalities associated with intravenous administration of doxycycline to horses and ponies. Equine Vet J 1992;24:41–5. https://doi.org/10.1111/j.2042-3306.1992.tb02777.x

54. Schölkens, B. Gerhards, H. Lindner E. Circulatory effects of intravenously administered rolitetracycline and other tetracyclines in animal experiments. Arzneimittelforschung 1971; 24(3):312–7.

55. Brouqui P, Raoult D. In vitro susceptibility of Ehrlichia sennetsu to antibiotics. Antimicrob Agents Chemother 1990; 34(8):1593–6. https://doi.org/10.1128/AAC.34.8.1593

56. Branger S, Rolain JM, Raoult D. Evaluation of antibiotic susceptibilities of Ehrlichia canis, Ehrlichia chaffeensis, and Anaplasma phagocytophilum by real-time PCR. Antimicrob Agents Chemother 2004; 48(12):4822–8. https://doi.org/10.1128/AAC.48.12.4822-4828.2004

57. Davoust B, Keundjian A, Rous V, Maurizi L, Parzy D. Validation of chemoprevention of canine monocytic ehrlichiosis with doxycycline. Vet Microbiol 2005;107(3–4):279–83. https://doi.org/10.1016/j.vetmic.2005.02.002

Descargas

La descarga de datos todavía no está disponible.

Artículos más leídos del mismo autor/a